FDA Approves TUKYSA® for Metastatic HER2-Positive Colorectal Cancer
Seagen Inc. announced FDA accelerated approval of TUKYSA for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer. It's the first FDA-approved treatment for HER2-positive metastat ...